• Explore /
  • Poster
  • / Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (<em>FGFRalt</em>) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results.

Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results.

Abstract Poster

Authors

null

Shubham Pant

The University of Texas MD Anderson Cancer Center, Houston, TX;

Shubham Pant , Martin H. Schuler , Gopa Iyer , Toshihiko Doi , Shukui Qin , Josep Tabernero , Dirk Arnold , Martin Gutierrez , Hans Prenen , Gunnar Folprecht , Helen Winter , Rasha Cosman , Graziela Zibetti Dal Molin , Qi Xia , Saltanat Najmi , Constance Hammond , Shibu Thomas , Spyros Triantos , Hussein Sweiti , Yohann Loriot

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Other

Clinical Trial Registration Number

NCT04083976

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 610)

DOI

10.1200/JCO.2023.41.4_suppl.610

Abstract #

610

Poster Bd #

G3

Abstract Disclosures

Similar Posters

First Author: Shubham Pant

First Author: Yin-Hsun Feng

First Author: Joon Oh Park

First Author: Junji Furuse